Je li H Lundbeck A/S dividenda sigurna?
H Lundbeck A/S povećava dividendu već 1 godina.
U posljednjih 10 godina, H Lundbeck A/S je ovo povećao/povećala za godišnjih −4,025 % snižen.
Na petogodišnjoj razini pao isplata se povećala za 0 %.
Analitičari za tekuću poslovnu godinu očekuju rast od Povećanje dividendi% na 82,576%.
H Lundbeck A/S Aktienanalyse
Što radi H Lundbeck A/S?
H Lundbeck A/S is a Danish company that was founded in 1915 by Hans Lundbeck. Since its inception, the company has focused on researching and developing medications that improve the lives of people with neuropsychiatric disorders.
Lundbeck's business model is based on a clear strategy and a strong focus on the research and development of pharmaceuticals. The company has four main therapy areas: depression, anxiety disorders, Alzheimer's, and Parkinson's. Lundbeck products are sold in over 100 countries worldwide and are known for their effectiveness and high quality.
Over the years, Lundbeck has also focused on developing innovative treatment methods, including research on new drugs and therapies based on neurotransmitters such as serotonin, dopamine, and norepinephrine. With the acquisition of Alder BioPharmaceuticals in 2019, Lundbeck also expanded its portfolio in the field of migraine therapy.
Some of Lundbeck's most well-known products include Lexapro, Cipralex, Selincro, Abilify Maintena, and Brintellix. These medications are used in the treatment of depression, anxiety disorders, alcoholism, bipolar disorders, and migraines. In addition to selling medications, Lundbeck also provides training and support for healthcare professionals and patients.
Lundbeck is also distinguished by its commitment to social engagement and works closely with nonprofit organizations to raise awareness of neuropsychiatric disorders. The company has also launched various programs to improve access to medical care in particularly affected regions.
In 2020, Lundbeck exceeded 18,000 employees worldwide and had a revenue of 16.6 billion Danish kroner. Lundbeck is listed on NASDAQ OMX Copenhagen and is controlled by the Lundbeck Foundation, which holds over 70% of the company's ownership.
In summary, Lundbeck is a leading company in the field of neuropsychiatric medicine and is dedicated to improving the lives of people with these serious disorders. The company has made a name for itself through its successful research and development of therapies and medications, as well as its strong focus on social engagement and corporate social responsibility. H Lundbeck A/S je jedna od najpopularnijih kompanija na Eulerpool.com.Aktiensparpläne nude atraktivnu mogućnost za investitore za dugoročno stvaranje imovine. Jedna od glavnih prednosti je tzv. efekt prosječenja troškova: investirajući redovito fiksni iznos u dionice ili dioničke fondove, automatski se kupuje više udjela kada su cijene niske, a manje kada su visoke. To može dovesti do povoljnijeg prosječnog cijene po udjelu tijekom vremena. Osim toga, Aktiensparpläne omogućavaju i malim investitorima pristup skupim dionicama, jer mogu sudjelovati već s malim iznosima. Redovita investicija također promiče discipliniranu strategiju ulaganja i pomaže izbjeći emocionalne odluke, poput impulzivne kupnje ili prodaje. Pored toga, investitori profitiraju od potencijalnog povećanja vrijednosti dionica kao i od isplata dividendi koje mogu biti reinvestirane, što pojačava učinak kamatnog kamata i time rast uloženog kapitala.
Dionica H Lundbeck A/S je dostupna za štedne planove kod sljedećih pružatelja usluga: Trade Republic